Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.64 |
| ▸ | SMO | Q99835 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476182 | 0.96 | MAPK14 (0.69) | MAPK14SMOOPRK1MEN1NPC1 | |
| SCHEMBL6485519 | 0.84 | MAPK14 (0.89) | MAPK14SMOMEN1KMT2ARAF1 | |
| SCHEMBL6782804 | 0.84 | MAPK14 (0.73) | MAPK14SMONPC1RAB9ARAF1 | |
| SCHEMBL6476015 | 0.83 | MAPK14 (0.65) | MAPK14SMOOPRK1MEN1NPC1 | |
| SCHEMBL6487036 | 0.82 | MAPK14 (0.66) | MAPK14SMOOPRK1MEN1NPC1 | |
| SCHEMBL6486377 | 0.82 | MAPK14 (0.63) | MAPK14SMOOPRK1MEN1NPC1 | |
| SCHEMBL6477567 | 0.81 | MAPK14 (0.62) | MAPK14SMOOPRK1RAF1BRAF | |
| SCHEMBL27480812 | 0.80 | MAPK14 (0.69) | MAPK14SMORAB9ARAF1BRAF | |
| SCHEMBL6484389 | 0.79 | MAPK14 (0.70) | MAPK14SMORAB9ARAF1BRAF | |
| SCHEMBL6478056 | 0.79 | MAPK14 (0.68) | MAPK14SMORAB9ARAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | MAPK14 2054/4885SMO 4147/4885OPRK1 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.